FDA Grants NeoVista’s Request To Utilize Novel Wet AMD Treatment In Compassionate Case

NeoVista, Inc., announced that the U.S. Food and Drug Administration (FDA) had approved the company’s “compassionate case” waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols. The patient received NeoVista’s therapy today in Nashville, Tenn.; the procedure was performed by Dr.

More: continued here

Filed under: Clinical Trials on December 11th, 2008